Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers DOI Creative Commons
Yu Zhang, Ke Qiu, Jiayuan Ai

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(4)

Published: April 1, 2025

Abstract Background High‐risk human papillomavirus (HPV), especially HPV16, is closely correlated with certain cancers. E6 and E7 proteins of HPV16 play critical roles in oncogenesis, making them optimal targets for treating HPV‐associated Here, we engineered an innovative vaccine, Ad‐E6/7‐HR, designed to evoke immune responses through the incorporation self‐assembling heptad‐repeat 1 (HR1) HR2 originated from Severe acute respiratory syndrome coronavirus 2. Methods Ad‐E6/7‐HR was constructed utilising a replication‐defective adenovirus serotype 5 vector evaluated its immunogenicity therapeutic efficacy murine models. We verified antitumour vaccine TC‐1 subcutaneous pulmonary Flow cytometry, enzyme‐linked immunospot assay, immunofluorescence staining were used assess cellular Ad‐E6/7‐HR. Results induced robust responses, significantly increasing antigen‐specific CD8 + T cells. The also enhanced memory T‐cell generation potent cytokine secretion, as exemplified by interferon‐γ tumour necrosis factor‐α. conferred complete protection against growth prophylactic model. In settings, reduced size improved survival. Furthermore, reshaped microenvironment increased recruitment immunosuppressive cells, like myeloid‐derived suppressor cells M2 macrophages, thereby enhancing immunity. Conclusions By targeting leveraging HR1 sequences enhance represented promising candidate preventing Further clinical investigation warranted evaluate potential trials.

Language: Английский

HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask DOI
Daniela Alterio,

Michał Gola,

Mattia Zaffaroni

et al.

Clinical & Translational Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Language: Английский

Citations

0
Human Papilloma Virus Genotypes Associated with Non-Cervical HPV Positive Cancer Development in UK and Ireland Cohorts: A Systematic Review DOI Creative Commons

Mary G. Mallon,

Mohammad Albraikat,

Andrew T. Kunzmann

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Abstract Background Human Papillomavirus (HPV) is an infectious agent notably associated with viral carcinogenesis of the cervix. Since 2019, UK and Ireland have used Gardasil-9 HPV vaccine to prevent new cases HPV-positive cancers. This systematic review aims assess whether current vaccination programme provides substantive protection against developing non-cervical Methods Relevant studies were identified using OVID-Medline EMBASE databases. Screening data extraction conducted software Covidence. Risk bias was assessed Hoy et al. tool, statistical analysis R (v 4.3.1). Results Based on pre-defined search parameters, 4,086 papers for screening. Following title, abstract, full-text review, extracted from 30 eligible studies. A total 1,411 patients cancers, 24 unique genotypes, considered in this review. The most prevalent genotype across all HPV16 (94.3%, 1332/1411). Genotypic diversity greater oropharyngeal penile cancers compared other HPV-related present study, nine genotypes reported these sites alone (p=0.3). found offer 37.5% (9/24) identified. However, if had been available, there would sufficient genotype-specific 9 out 10 (96.3%, 1359/1411) retrospectively study. It should be noted that significant regional differences heterogeneity (p<0.001) illustrated, London-based cohorts having unprotected (4.7%, 31/658). Conclusion confirms as dominant highlights genotypic Moreover, while limited protection, it could prevented nearly Regional minimal, but London highest proportion genotypes. suggests highly effective preventing gaps remain, particularly less common

Language: Английский

Citations

0
Prevalence and Genotype Distribution of High-Risk HPV Genotypes Among Women in Greece: A Retrospective Analysis of 3500 Women DOI Open Access
D. Tsakogiannis, Eleni Zografos,

Lamprini Tzioga

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1267 - 1267

Published: April 9, 2025

Background/Objectives: Persistent infection with high-risk (HR) HPV genotypes is the main risk factor for development of cervical cancer. The present analysis provides recent trends on HR-HPV rates and distribution among 3500 Greek women between 2021 2023. Methods: detection HR-HPVs specific identification HPV16 HPV18 were conducted using Roche Cobas 4800 assay. genotyping 12 other was performed through Nested Multiplex PCR methodology (NMPCR). Results: overall rate 8.8% most prevalent genotype being followed by HPV31, HPV66, HPV56, HPV51, HPV58, HPV45, HPV18, HPV68, HPV59, HPV52, HPV35, HPV39, HPV33. Among HR-HPV-positive cases prevalence single, double, triple, quadruple infections 73.9%, 19.9%, 5.5%, 0.7%, respectively. Age-specific showed that higher in age group 31–35 years (25.5%) it estimated multiple occur more often younger women. Notably, varies different groups. It proposed HPV16, HPV66 may show an increased possibility establishing long-term over 36 old. Conclusions: high which are not included prophylactic vaccines underlines significance constant surveillance circulating HPVs population.

Language: Английский

Citations

0
Altered expression of collagen gene family members and its epigenetic background in equine Sarcoids DOI
Klaudia Pawlina‐Tyszko, Ewelina Semik‐Gurgul,

Przemysław Podstawski

et al.

Research in Veterinary Science, Journal Year: 2025, Volume and Issue: unknown, P. 105656 - 105656

Published: April 1, 2025

Language: Английский

Citations

0
Ad‐E6/7‐HR vaccine improves the prophylactic and therapeutic efficacy in HPV‐associated cancers DOI Creative Commons
Yu Zhang, Ke Qiu, Jiayuan Ai

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(4)

Published: April 1, 2025

Abstract Background High‐risk human papillomavirus (HPV), especially HPV16, is closely correlated with certain cancers. E6 and E7 proteins of HPV16 play critical roles in oncogenesis, making them optimal targets for treating HPV‐associated Here, we engineered an innovative vaccine, Ad‐E6/7‐HR, designed to evoke immune responses through the incorporation self‐assembling heptad‐repeat 1 (HR1) HR2 originated from Severe acute respiratory syndrome coronavirus 2. Methods Ad‐E6/7‐HR was constructed utilising a replication‐defective adenovirus serotype 5 vector evaluated its immunogenicity therapeutic efficacy murine models. We verified antitumour vaccine TC‐1 subcutaneous pulmonary Flow cytometry, enzyme‐linked immunospot assay, immunofluorescence staining were used assess cellular Ad‐E6/7‐HR. Results induced robust responses, significantly increasing antigen‐specific CD8 + T cells. The also enhanced memory T‐cell generation potent cytokine secretion, as exemplified by interferon‐γ tumour necrosis factor‐α. conferred complete protection against growth prophylactic model. In settings, reduced size improved survival. Furthermore, reshaped microenvironment increased recruitment immunosuppressive cells, like myeloid‐derived suppressor cells M2 macrophages, thereby enhancing immunity. Conclusions By targeting leveraging HR1 sequences enhance represented promising candidate preventing Further clinical investigation warranted evaluate potential trials.

Language: Английский

Citations

0